Absci Corporation.(ABSI)

POST3.180.04+1.26%19:59 EDT

3.14+0.24+8.28%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Absci Corp expected to post a loss of 24 cents a share - Earnings Preview
  Reuters · 03-14 20:36
  Absci Corp expected to post a loss of 24 cents a share - Earnings Preview
- Calendar of U.S. Earnings Expected in the Week Ahead
  Dow Jones · 03-14 10:00
  Calendar of U.S. Earnings Expected in the Week Ahead
- BRIEF-Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
  Reuters · 03-04
  BRIEF-Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
- Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025
  GlobeNewswire · 03-04
  Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025
- Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
  THOMSON REUTERS · 03-04
  Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
- Why Absci Corporation (ABSI) is Skyrocketing So Far in 2025
  Insider Monkey · 03-01
  Why Absci Corporation (ABSI) is Skyrocketing So Far in 2025
- Is Absci Corp. (ABSI) the Best Nasdaq Stock Under $5 to Buy?
  Insider Monkey · 02-12
  Is Absci Corp. (ABSI) the Best Nasdaq Stock Under $5 to Buy?
- Absci Corporation (ABSI): Pioneering AI-Driven Antibody Discovery with a ‘Buy’ Rating from Needham
  Insider Monkey · 01-24
  Absci Corporation (ABSI): Pioneering AI-Driven Antibody Discovery with a ‘Buy’ Rating from Needham
- Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
  Benzinga · 01-22
  Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
- H.C. Wainwright Reaffirms Their Buy Rating on AbSci (ABSI)
  TIPRANKS · 01-22
  H.C. Wainwright Reaffirms Their Buy Rating on AbSci (ABSI)
- Needham & Co Initiates Coverage on Absci With Buy Rating, $9 Price Target
  MT Newswires Live · 01-22
  Needham & Co Initiates Coverage on Absci With Buy Rating, $9 Price Target
- Absci Corp : Needham Initiates Coverage With Buy Rating; Target Price $9
  THOMSON REUTERS · 01-22
  Absci Corp : Needham Initiates Coverage With Buy Rating; Target Price $9
- BUZZ-Absci Corp rises after Needham initiates coverage with 'buy' rating
  Reuters · 01-22
  BUZZ-Absci Corp rises after Needham initiates coverage with 'buy' rating
- Absci Corp Shares up 4% Premarket After Needham Initiates Coverage With Buy Rating
  THOMSON REUTERS · 01-22
  Absci Corp Shares up 4% Premarket After Needham Initiates Coverage With Buy Rating
- Absci initiated with a Buy at Needham
  TIPRANKS · 01-22
  Absci initiated with a Buy at Needham
- AbSci (ABSI) Gets a Buy from Truist Financial
  TIPRANKS · 01-21
  AbSci (ABSI) Gets a Buy from Truist Financial
- Absci Corporation (ABSI): AI in Biopharma Discovery
  Insider Monkey · 01-17
  Absci Corporation (ABSI): AI in Biopharma Discovery
- Absci Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
  Dow Jones · 01-17
  Absci Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
- Absci, Owkin announce partnership to bring together AI platforms
  TipRanks · 01-11
  Absci, Owkin announce partnership to bring together AI platforms
- Advanced Micro Devices (AMD) Invests in Absci for AI-Driven Drug Discovery with High-Performance Computing Solutions
  Insider Monkey · 01-10
  Advanced Micro Devices (AMD) Invests in Absci for AI-Driven Drug Discovery with High-Performance Computing Solutions
Company Profile
Company Name
Absci Corporation.
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.absci.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has a collaboration with Memorial Sloan Kettering Cancer Center to discover novel therapeutics using generative AI; with AstraZeneca PLC for AI-driven drug discovery against an oncology target; and with Twist Bioscience Corporation to design a novel therapeutic using generative AI. The company was founded in 2011 and is headquartered in Vancouver, Washington.
- 01-15
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-11-14
  Beneficial Ownership Change
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
- 2024-11-12
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2024-11-12
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-09-04
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-08-14
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2024-08-14
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-06-14
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-06-13
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 2024-05-14
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2024-05-14
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-03-21
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 2024-03-21
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-03-21
  Annual Report
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
- 2024-03-05
  Beneficial Ownership Change
  Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
  Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

1D
5D
Day
Week
Month

Loading ...

High

3.21

Open

2.98

Volume%

1.45

Low

2.90

T/O Rate

5.81%

抱歉，当前请求异常(-1)

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

Absci Corporation.(ABSI)

Company Profile